Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL CongressBusiness Wire • 05/29/24
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 05/08/24
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences ConferenceBusiness Wire • 05/07/24
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFICBusiness Wire • 05/07/24
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024Business Wire • 05/01/24
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/25/24
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive ValueSeeking Alpha • 04/22/24
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille SyndromeBusiness Wire • 04/02/24
Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic CholestasisBusiness Wire • 03/13/24
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business UpdateBusiness Wire • 02/28/24
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024Business Wire • 02/21/24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate UpdatesBusiness Wire • 01/08/24
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/24